{"protocolSection": {"identificationModule": {"nctId": "NCT01068743", "orgStudyIdInfo": {"id": "CV181-121"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered", "officialTitle": "Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 850 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 850 mg Metformin (Glucophage Marketed by Merck Serono) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed Conditions"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-12", "studyFirstSubmitQcDate": "2010-02-12", "studyFirstPostDateStruct": {"date": "2010-02-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-01-09", "resultsFirstSubmitQcDate": "2012-01-09", "resultsFirstPostDateStruct": {"date": "2012-02-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-21", "lastUpdatePostDateStruct": {"date": "2015-05-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet co-administered to healthy subjects in the fasted and fed condition."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 24, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)", "type": "OTHER", "description": "A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.", "interventionNames": ["Drug: saxagliptin", "Drug: metformin"]}, {"label": "Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)", "type": "OTHER", "description": "A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.", "interventionNames": ["Drug: saxagliptin + metformin (FDC tablet)"]}, {"label": "Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)", "type": "OTHER", "description": "A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.", "interventionNames": ["Drug: saxagliptin", "Drug: metformin"]}, {"label": "Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)", "type": "OTHER", "description": "A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.", "interventionNames": ["Drug: saxagliptin + metformin (FDC tablet)"]}], "interventions": [{"type": "DRUG", "name": "saxagliptin", "description": "Tablets, Oral, 2.5 mg, once daily, single dose", "armGroupLabels": ["Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)", "Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "metformin", "description": "Tablets, Oral, 850 mg, once daily, single dose", "armGroupLabels": ["Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)", "Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "saxagliptin + metformin (FDC tablet)", "description": "Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose", "armGroupLabels": ["Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)", "Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Metformin PK Parameter AUC(0-inf)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Metformin PK Parameter Cmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}], "secondaryOutcomes": [{"measure": "5-hydroxy Saxagliptin PK Parameter AUC(0-inf)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "5-hydroxy Saxagliptin PK Parameter Cmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\\[0-t\\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.", "timeFrame": "AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening)."}, {"measure": "Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities", "description": "Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.", "timeFrame": "From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening)."}], "otherOutcomes": [{"measure": "Saxagliptin PK Parameter AUC(0-t)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Saxagliptin PK Parameter T1/2", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Saxagliptin PK Parameter Tmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Metformin PK Parameter AUC(0-t)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Metformin PK Parameter T1/2", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}, {"measure": "Metformin PK Parameter Tmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women ages 18 to 55 inclusive\n* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations\n* Body Mass Index (BMI) of 18 to 32 kg/m\\^2, inclusive. BMI = weight (kg)/ \\[height (m)\\]\\^2\n\nExclusion Criteria:\n\n* Any significant acute or chronic medical illness\n* Current or recent (within 3 months) gastrointestinal disease\n* Any major surgery within 4 weeks of study drug administration\n* History of allergy to a dipeptidyl peptidase-IV (DPP4) inhibitor or related compound\n* History of allergy or intolerance to metformin or other similar acting agents\n* Prior exposure to saxagliptin\n* Prior exposure to metformin within 3 months of study drug administration\n* Estimated creatinine clearance (Clcr) of \\< 80 mL/min using the Cockcroft Gault formula", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "PPD Development, LP", "city": "Austin", "state": "Texas", "zip": "78744", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were screened for eligibility within 21 days before Day 1 of period 1. On Day -1 of each period, the participants were admitted to the clinical facility and confined for 4 days. All the 24 participants were randomly assigned to 1 of 4 treatment sequences (ADBC, BACD, CBDA, or DCAB). The washout between each dose was at least 7 days.", "recruitmentDetails": "Participants (N = 24) who met all of the inclusion and none of the exclusion criteria were recruited from a single site in the United States.", "groups": [{"id": "FG000", "title": "Treatment Sequence ADBC", "description": "Treatment A (period 1): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition; Treatment D (period 2): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition; Treatment B (period 3): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition; Treatment C (period 4): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition."}, {"id": "FG001", "title": "Treatment Sequence BACD", "description": "Treatment B (period 1): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition; Treatment A (period 2): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition; Treatment C (period 3): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition; Treatment D (period 4): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition."}, {"id": "FG002", "title": "Treatment Sequence CBDA", "description": "Treatment C (period 1): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition; Treatment B (period 2): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition; Treatment D (period 3): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition; Treatment A (period 4): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition."}, {"id": "FG003", "title": "Treatment Sequence DCAB", "description": "Treatment D (period 1): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition; Treatment C (period 2): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition; Treatment A (period 3): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition; Treatment B (period 4): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Enrolled and Treated Participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.5", "spread": "10.61"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "13"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "21"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.2", "spread": "12.0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.7", "spread": "13.7"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.4", "spread": "3.05"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "49.23", "spread": "18.52"}, {"groupId": "OG001", "value": "49.94", "spread": "19.72"}, {"groupId": "OG002", "value": "52.50", "spread": "17.95"}, {"groupId": "OG003", "value": "53.15", "spread": "17.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% confidence intervals (CIs) for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "101.45", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "98.17", "ciUpperLimit": "104.84", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries. LS=Least Squares."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf,respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "102.43", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "99.53", "ciUpperLimit": "105.42", "estimateComment": "Ratio=Treatment D/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "49.23"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "49.94"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares means for Treatment C.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "52.71"}, {"groupIds": ["OG003"], "groupDescription": "Geometric least squares means for Treatment D.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "53.99"}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin PK Parameter AUC(0-inf)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "118.58", "spread": "24.08"}, {"groupId": "OG001", "value": "119.54", "spread": "21.16"}, {"groupId": "OG002", "value": "121.99", "spread": "25.42"}, {"groupId": "OG003", "value": "125.54", "spread": "24.82"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin PK Parameter Cmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.83", "spread": "32.95"}, {"groupId": "OG001", "value": "16.72", "spread": "32.92"}, {"groupId": "OG002", "value": "17.35", "spread": "32.95"}, {"groupId": "OG003", "value": "18.59", "spread": "30.78"}]}]}]}, {"type": "PRIMARY", "title": "Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.73", "spread": "20.44"}, {"groupId": "OG001", "value": "9.97", "spread": "29.07"}, {"groupId": "OG002", "value": "10.25", "spread": "26.87"}, {"groupId": "OG003", "value": "10.88", "spread": "23.72"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "102.46", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "94.68", "ciUpperLimit": "110.88", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "106.24", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "98.43", "ciUpperLimit": "114.66", "estimateComment": "Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng/mL)", "paramValue": "9.73"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng/mL)", "paramValue": "9.97"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares means for Treatment C.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng/mL)", "paramValue": "10.33"}, {"groupIds": ["OG003"], "groupDescription": "Geometric least squares means for Treatment D.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng/mL)", "paramValue": "10.97"}]}, {"type": "PRIMARY", "title": "Metformin PK Parameter AUC(0-inf)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11998.00", "spread": "23.68"}, {"groupId": "OG001", "value": "12271.61", "spread": "20.42"}, {"groupId": "OG002", "value": "11988.30", "spread": "16.94"}, {"groupId": "OG003", "value": "11838.11", "spread": "18.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "102.10", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "97.26", "ciUpperLimit": "107.18", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "99.17", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.23", "ciUpperLimit": "102.21", "estimateComment": "Ratio=Treatment D/Treatment C. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares mean for Treatment A.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "11998"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "12250"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares means for Treatment C.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "12036"}, {"groupIds": ["OG003"], "groupDescription": "Geometric least squares means for Treatment D.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "11937"}]}, {"type": "PRIMARY", "title": "Metformin PK Parameter Cmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition."}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition."}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1724.38", "spread": "25.49"}, {"groupId": "OG001", "value": "1715.79", "spread": "23.59"}, {"groupId": "OG002", "value": "1571.21", "spread": "15.64"}, {"groupId": "OG003", "value": "1541.76", "spread": "17.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "99.50", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "90.41", "ciUpperLimit": "109.5", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "98.22", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "94.28", "ciUpperLimit": "102.32", "estimateComment": "Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng/mL", "paramValue": "1724.4"}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Square Means (ng/mL)", "paramValue": "1715.8"}, {"groupIds": ["OG002"], "groupDescription": "Geometric least squares means for Treatment C.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Square Mean (ng/mL)", "paramValue": "1581.4"}, {"groupIds": ["OG003"], "groupDescription": "Geometric least squares means for Treatment D.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng/mL)", "paramValue": "1553.2"}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\\[0-t\\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "109.60", "spread": "25.81"}, {"groupId": "OG001", "value": "110.61", "spread": "22.77"}, {"groupId": "OG002", "value": "113.15", "spread": "26.53"}, {"groupId": "OG003", "value": "117.04", "spread": "25.74"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hr", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.58", "spread": "1.32"}, {"groupId": "OG001", "value": "7.58", "spread": "1.35"}, {"groupId": "OG002", "value": "7.48", "spread": "1.10"}, {"groupId": "OG003", "value": "7.22", "spread": "1.01"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hr", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.21", "spread": "0.75"}, {"groupId": "OG001", "value": "1.86", "spread": "0.71"}, {"groupId": "OG002", "value": "2.65", "spread": "0.83"}, {"groupId": "OG003", "value": "2.46", "spread": "0.72"}]}]}]}, {"type": "SECONDARY", "title": "Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.", "populationDescription": "All participants who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"title": "Number of Participants With at Least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "4"}]}]}, {"title": "Discontinuation Due to AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Saxagliptin PK Parameter AUC(0-t)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.15", "spread": "17.98"}, {"groupId": "OG001", "value": "47.83", "spread": "19.77"}, {"groupId": "OG002", "value": "50.69", "spread": "17.74"}, {"groupId": "OG003", "value": "51.37", "spread": "17.63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "101.43", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "98.07", "ciUpperLimit": "104.90", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG002", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "102.52", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "99.56", "ciUpperLimit": "105.57", "estimateComment": "Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "47.15", "estimateComment": "Geometric least squares means for Treatment A."}, {"groupIds": ["OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "47.83", "estimateComment": "Geometric least squares means for Treatment B."}, {"groupIds": ["OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "50.89", "estimateComment": "Geometric least squares means for Treatment C."}, {"groupIds": ["OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "52.17", "estimateComment": "Geometric least squares means for Treatment D."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Saxagliptin PK Parameter T1/2", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hr", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.45", "spread": "1.00"}, {"groupId": "OG001", "value": "6.21", "spread": "1.25"}, {"groupId": "OG002", "value": "5.86", "spread": "0.92"}, {"groupId": "OG003", "value": "6.09", "spread": "0.94"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Saxagliptin PK Parameter Tmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hr", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.38", "spread": "0.79"}, {"groupId": "OG001", "value": "0.96", "spread": "0.61"}, {"groupId": "OG002", "value": "1.94", "spread": "0.95"}, {"groupId": "OG003", "value": "1.48", "spread": "0.58"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Metformin PK Parameter AUC(0-t)", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11826.52", "spread": "23.86"}, {"groupId": "OG001", "value": "11875.08", "spread": "21.47"}, {"groupId": "OG002", "value": "11796.60", "spread": "17.03"}, {"groupId": "OG003", "value": "11681.05", "spread": "17.59"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "100.41", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "95.40", "ciUpperLimit": "105.68", "estimateComment": "Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG002", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio (%) of Geometric LS Means", "paramValue": "99.06", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.19", "ciUpperLimit": "102.02", "estimateComment": "Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "11827", "estimateComment": "Geometric least squares means for Treatment A."}, {"groupIds": ["OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "11875", "estimateComment": "Geometric least squares means for Treatment B."}, {"groupIds": ["OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "11845", "estimateComment": "Geometric least squares means for Treatment C."}, {"groupIds": ["OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*h/mL)", "paramValue": "11734", "estimateComment": "Geometric least squares means for Treatment D."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Metformin PK Parameter T1/2", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.", "populationDescription": "All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hr", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.94", "spread": "4.13"}, {"groupId": "OG001", "value": "13.15", "spread": "6.67"}, {"groupId": "OG002", "value": "10.82", "spread": "3.18"}, {"groupId": "OG003", "value": "11.13", "spread": "3.08"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Metformin PK Parameter Tmax", "description": "PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.", "populationDescription": "All treated participants not discontinuing prior to the end of the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hr", "timeFrame": "Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.41", "spread": "0.78"}, {"groupId": "OG001", "value": "2.54", "spread": "0.92"}, {"groupId": "OG002", "value": "3.74", "spread": "0.54"}, {"groupId": "OG003", "value": "3.74", "spread": "0.45"}]}]}]}, {"type": "SECONDARY", "title": "Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities", "description": "Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.", "populationDescription": "All participants who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).", "groups": [{"id": "OG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition"}, {"id": "OG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition"}, {"id": "OG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition"}, {"id": "OG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "23"}]}], "classes": [{"title": "Clinical Laboratory Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Vital Sign Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Physical Examination Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "12-Lead ECG Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).", "eventGroups": [{"id": "EG000", "title": "Treatment A", "description": "2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 4, "otherNumAtRisk": 24}, {"id": "EG001", "title": "Treatment B", "description": "Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 5, "otherNumAtRisk": 24}, {"id": "EG002", "title": "Treatment C", "description": "2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 3, "otherNumAtRisk": 23}, {"id": "EG003", "title": "Treatment D", "description": "FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 4, "otherNumAtRisk": 23}], "otherEvents": [{"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 23}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Muscle strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Synovial cyst", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Vessel puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 23}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period of \\<= 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trail's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}